EGFR and non-small cell lung carcinoma: Although API was recently shown to inhibit proliferation by targeting Akt in NSCLC cells harboring the wild-type EGFR [30], whether API has a broad impact on NSCLC with different EGFR mutation statuses, how API impacts the metastatic ability of NSCLC cells in vivo, and what the underlying mechanisms of API are in regulating Akt activity and modulating cell motility are still undefined.